Bioman Biotech

Bioman Biotech is a clinical-stage biotechnology company based in Shanghai, specialized in developing advanced cell and gene therapies (CGT) using non-viral technologies. The company’s core innovation is the proprietary Super-N platform, a non-viral gene insertion system designed to offer a safer and more efficient alternative to traditional viral vectors for therapeutic gene delivery. Bioman Biotech focuses on engineering high-precision CAR-T and TCR-T therapies for both hematological malignancies and challenging solid tumors, such as liver cancer. Their lead program, BM-001, utilizes this non-viral approach to target B-cell malignancies and is currently in clinical development. By optimizing the genetic modification process, Bioman Biotech aims to reduce the complexity and cost of CGT manufacturing while improving patient safety and efficacy.